Siltuximab Pivotal Trial Data Show Efficacy For Treatment Of Patients With Multicentric Castleman's Disease
Janssen Research & Development is part of the Janssen Pharmaceutical Companies. Please visit http://www.janssenrnd.com for more information.
1 Wong RS et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman's Disease. Oral presentation presented at: 55 th American Society of Hematology (ASH) Annual Meeting; Dec. 7-11, 2013; New Orleans, LA.
2 American Cancer Society. What is Castleman disease? Available from: http://www.cancer.org/cancer/castlemandisease/detailedguide/castleman-disease-what-is-castleman-disease. Accessed August 20133 Memorial Sloan Kettering Cancer Center. Uncommon Lymphoproliferative Disorders. Available from: http://www.mskcc.org/cancer-care/adult/rare-hematologic-disorders/uncommon-lymphoproliferative-disorders. Accessed August 2013. 4 Van Rhee F et al. An Open-Label, Phase 2, Multicenter Study Of The Safety Of Long-Term Treatment With Siltuximab (an Anti-Interleukin-6 Monoclonal Antibody) In Patients With Multicentric Castleman's Disease. Poster presentation presented at: 55 th American Society of Hematology (ASH) Annual Meeting; Dec. 7-11, 2013; New Orleans, LA. 5 American Cancer Society. How is Castleman disease diagnosed? Available from: http://www.cancer.org/cancer/castlemandisease/detailedguide/castleman-disease-diagnosis Accessed October 2013 6 El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist. 2011;16(4):497-511. 7 Peterson, B. Seminars in Oncology. Multicentric Castleman's disease. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8296200 Accessed October 2013 8 Greiner, T. Hematology Am Soc Hematol Educ Program. Atypical Lymphoproliferative Diseases. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11701539 Accessed October 2013 9 National Center for Advancing Translational Sciences. Multicentric Castleman's Disease. Available from: http://rarediseases.info.nih.gov/gard/9644/idiopathic-multicentric-castlemans-disease/resources/1 Accessed November 2013. 10 American Cancer Society. Treatment of localized (unicentric) Castleman disease. Available from: http://www.cancer.org/cancer/castlemandisease/detailedguide/castleman-disease-treating-treating-localized. Accessed October 2013 11 American Cancer Society. Treatment of multicentric Castleman disease. Available from: http://www.cancer.org/cancer/castlemandisease/detailedguide/castleman-disease-treating-treating-multicentric. November October 2013 12 American Cancer Society. What are the key statistics about Castleman disease? Available from: http://www.cancer.org/cancer/castlemandisease/detailedguide/castleman-disease-key-statistics . Accessed November 2013 Note: Data in this release correspond to ASH Abstracts 1806 and 505. U.S. Media Inquiries: Ilona RubinoPhone: 1-215-793-7227Mobile : 1-484-678-8698 EU Media Inquiries: Satu GlawePhone: 49-2638-947-9218 Investor Relations: Stan PanasewiczPhone: 1-732-524-2524 Louise MehrotraPhone: 1-732-524-6491 U.S. Medical Inquiries:1-800-526-7736 SOURCE Janssen Research & Development, LLC
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV